US Markets

EARNINGS-Regeneron profit rises nearly 13% on higher demand for eczema drug Dupixent

Credit: REUTERS/Shailesh Andrade

Regeneron Pharmaceuticals Inc reported a 12.6% rise in third-quarter profit on Tuesday, boosted by higher sales of its eczema drug, Dupixent.

Nov 5 - Regeneron Pharmaceuticals Inc REGN.O reported a 12.6% rise in third-quarter profit on Tuesday, boosted by higher sales of its eczema drug, Dupixent.

Net income rose to $669.6 million, or $5.86 per share, in the quarter ended Sept. 30, from $594.7 million, or $5.17 per share, a year earlier.

Total revenue rose 23.1% to $2.05 billion.

(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)

((Manas.Mishra@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 806749 8325;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More